Ravulizumab: First Global Approval
暂无分享，去创建一个
[1] H. Schrezenmeier,et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. , 2019, Blood.
[2] R. Wells,et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. , 2019, Blood.
[3] R. Wells,et al. Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies , 2018, Blood.
[4] R. Wells,et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. , 2018, Blood advances.
[5] Zhao-Xue Yu,et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action , 2018, PloS one.
[6] T. Kinoshita,et al. Paroxysmal nocturnal haemoglobinuria , 2017, Nature Reviews Disease Primers.